CN1311850C - External use medicinal composition for treating swelling paint - Google Patents

Abstract

The present invention relates to a medicinal composition for treating swelling paint, particularly to an external medicinal composition for treating swelling paint, which uses vegetal Chinese herbal medicines as raw materials. The external medicinal composition for treating swelling paint, which is provided by the present invention, is in an external dosage form and is composed of the following raw materials with the weight proportioning: 160 to 200g of scandent schefflera roots, 160 to 200g of radices pseudoginseng, 160 to 200g of shortstalk monkshood roots, 160 to 200g of delivery ampelopsis roots, 160 to 200g of yunnan craibiodendron leaves, 160 to 200g of tali falsehellebore herb, 160 to 200g of tuniclike psammosilene roots, 160 to 200g of aconitum vilmorinianum komar, 160 to 200g of tripterygium hypoglaucum, 160 to 200g of fleabane, 160 to 200g of dysosma versipellis, 160 to 200g of paris rhizome, 160 to 200g of fructus gardeniae, 160 to 200g of bletillae rhizoma, 160 to 200g of dahurian angelica roots, 50 to 70g of licorice roots, 50 to 70g of borneol, 50 to 70g of mentha camphor, and 0.4 to 1g of musk. The medicinal composition of the present invention can be used for treating diseases, such as traumatic injury, rheumatic arthritis, scapulohumeral periarthritis, gout, hyperplasia of lobuli glandulae mammariae, etc.

Description

External pharmaceutical composition for treating swelling and pain

technical field

The invention relates to a medicinal composition for treating swelling and pain, in particular to an external medicinal composition for treating swelling and pain which is made from plant and Chinese herbal medicine.

Background technique

Chinese Patent Application No. 931112052 discloses "a preparation method of burn and scald medicine", which involves soaking burnt elm, cortex cortex, elm inner bark and/or jujube inner bark, borneol and notoginseng in alcohol to prepare a burn and scald medicine. The proportion of each component of the medicinal materials is as follows: 70-100 parts of Burnet, 50-100 parts of Cortex Phellodendri, 1-60 parts of elm inner bark and/or jujube inner bark, 0.1-2 parts of Borneol, and 0.1-2 parts of Panax notoginseng. Chinese Patent Application No. 02158235.1 discloses a "medicinal composition for external use for the treatment of swelling and pain", which consists of Aescinus 72-288, Jade Grape Root 72-288, Golden Leaf 72-288, Phimacao 72-288, Jin Tiesuo 72- 288 made.

Contents of the invention

The object of the present invention is to provide an externally applied pharmaceutical composition with remarkable curative effect and safe use for treating bruises and rheumatic pains.

The external pharmaceutical composition for treating swelling and pain of the present invention is an external dosage form made of the following raw materials in weight ratio: Aescin 160-200, Panax notoginseng 160-200, Artemisia spp. 160-200, Yu grape root 160-200, golden leaf 160-200, hemp grass 160-200, golden iron lock 160-200, Diancao 160-200, torch flower root 160-200, erigantula 160-200, star anise lotus 160-200, Chonglou 160-200, Mastia 160-200, Baiji 160-200, Angelica dahurica 160-200, Licorice 50-70, Borneol 50-70, Menthol 50-70, Musk 0.4-1.

The present invention uses Aescinus chinensis, Panax notoginseng and Artemisia aesculus as main medicines, and Aescinus aescini is sweet and warm, good at relieving pain and reducing swelling, relaxing tendons and activating collaterals, expelling wind and dehumidification, and is used for various pains, bruises, fractures and traumatic bleeding; three Seven sweets, slightly bitter, warm, are recognized ancient and modern as a good medicine for dispelling blood stasis, hemostasis, reducing swelling and relieving pain, and has the power of strengthening and strengthening the body; Artemisia sativa is bitter, pungent, warm, poisonous, and has strong power of dispelling rheumatism and analgesia; Both have strong blood circulation promoting and blood stasis dispelling, swelling and pain relieving, expelling wind and dampness effects and play the main therapeutic role. Grass Aconitum, Golden Tiesuo, Jade Grape Root, Golden Leaf, and Dengzhan Xixin are all warm and pungent products, which have the power of invigorating the body's yang energy. It has the effect of dispelling blood stasis and relieving pain; Chonglou, Huobahuagen, star anise lotus, and Pimacao are bitter and cold in nature and taste, good at clearing away heat and detoxifying, promoting blood circulation and dissipating blood stasis, reducing swelling and relieving pain, and are suitable for heat arthralgia (such as rheumatic fever, acute gouty arthritis and Shoulder periarthritis) and bruises and mammary gland hyperplasia have a direct effect of cooling blood, promoting blood circulation, reducing swelling and relieving pain, and can prevent pungent, warming and dredging medicines from consuming qi and damaging yin. The medicine can benefit the meridians, reduce swelling and relieve pain. Fructus Fructus Angelicae, Angelica dahurica, and Baiji are adjuvant medicines. Fructus Fructus Radix Angelicae Dahurica and Baiji are adjuvant medicines. Fructus Fructus Radix Angelicae Dahurica and Baizhi are bitter and cold, which can restrain the nature of warming and hot medicines that injure yin and transform dryness, and have the effect of adjuvant medicine. The mucous quality of Baizhi can make the medicinal liquid slightly viscous and act as a drug loader. Angelica dahurica relieves itching and can prevent itching embolism that may occur in a small number of people after taking medicine. Musk is pungent and warm. "Compendium of Materia Medica" says that it "opens all orifices, opens meridians, and penetrates muscles and bones". blood, promote transdermal absorption of drugs, and produce a cooling sensation on the skin to relieve discomfort and pain; licorice can not only clear away heat and detoxify, relieve spasms and relieve pain, but also reconcile the cold and heat properties of the drug, and alleviate the toxicity and potency of the drug. medicine.

The medicament of the present invention is the so-called external dosage form in pharmacy. It can be liniment, aerosol, film coating, adhesive plaster, cataplasm, gel, etc. made from the raw materials of the present invention and corresponding pharmaceutical excipients through conventional techniques.

The pharmaceutical composition of the present invention has been proved by toxicity test that external use has no toxic and side effects; by pharmacodynamics research, it has significant effects of anti-inflammation, analgesia, improving microcirculation, inhibiting gouty arthritis and inhibiting mammary gland hyperplasia; through clinical trials, The total effective rate for the treatment of bruises, rheumatoid arthritis, frozen shoulder, gout and breast lobular hyperplasia is over 92%.

Pharmacodynamic study

1. Research on anti-inflammatory effect

1. Effect on adjuvant arthritis in rats

Seventy rats of 150-200 g were used in the experiment, half male and half male, and the groupings are shown in Table 1. Except that the model control group was not given any treatment, the animals in each group were smeared below the ankle joint of the right hind foot according to the dosage once a day for 6 consecutive days. Before the last drug application, the normal volume of the left and right paws was measured. 30 minutes after the drug application, 0.1 ml of Freund's complete adjuvant was subcutaneously injected into the right hind foot of each rat, and the drug was applied continuously for 26 days after the inflammation was induced. Measure the volume of the left and right paws at intervals of 2h, 18h, 3d and later (see Table 1 and Table 2) after inducing inflammation. At the same time, pay attention to observe the swelling of the front feet, the erythema of the tail and ears and the change in body weight of the rats after 8 days of inducing inflammation. And according to literature standards, the delayed hypersensitivity reaction of each mouse was scored until 28 days after inflammation. On the 28th day, the animals were killed, and the thymus, spleen and adrenal gland were dissected and weighed, and the organ index and the swelling rate of the left and right feet before and after inflammation were calculated, and the significance of the differences between the groups was compared for each index. The results are shown in Table 1, Table 2, Table 3 and Table 4.

Experimental results show that the present invention can not only inhibit the primary lesion of rat adjuvant arthritis, but also significantly inhibit the contralateral paw swelling and re-paw swelling in the secondary lesion, and reduce the systemic pain in delayed hypersensitivity reaction. Symptoms, no significant impact on immune organs, adrenal gland weight and body weight.

Table 1. Effect of the present invention on the primary pathological changes of rat adjuvant arthritis

group Dosage (/piece) Number of animals (only) Basal foot volume (X±SD, ml) Swelling rate at different times after inflammation (X±SD,%) 2h 18h 3d 5d Model comparison 10 1.25±0.09 30.01±12.23 50.59±12.74 59.35±25.60 45.63±11.82 Solvent 0.1ml 10 1.26±0.11 40.54±19.97 50.67±18.01 56.98±22.12 53.33±16.0l e fluocinolone 50mg 10 1.25±0.06 31.22±10.64 38.61±6.39 ^* 35.48±16.21 ^* 33.82±12.22 ^*   Yunnan Baiyao tincture 0.1ml 10 1.23±0.12 40.7±15.76 44.07±18.34 56.13±23.57 54.41±22.88   The invention is 100% 0.1ml 10 1.34±0.13 26.77±8.19 33.55±18.25 38.90±15.49 33.98±17.31 50% of the invention 0.1m1 10 1.25±0.14 28.12±25.48 37.06±18.63  46.91±22.86 43.24±22.11   Invention 25% 0.1ml 10 1.28±0.16 32.48±14.62 44.44±20.07 37.07±15.39 ^* 40.58±18.32

Table 2. The present invention is to the influence of rat adjuvant arthritis secondary lesion

Group Dose (/piece) Number of animals (only)   Swelling rate at different times after inflammation (X±SD, 1D0%) 8d 12d 16d 20d 24d 28d Inflammatory right foot Model comparison 8 42.85±15.25 36.71±21.32 55.06±23.06 56.61±23.41 52.21±23.60 60.08±24.10 solvent 0.1ml 9 50.91±20.20 57.76±27.25 61.92±38.26 60.21±34.48 55.09±34.44 57.01±35.54 fluocinolone 50mg 8   22.01±13.20 22.42±11.94 15.23±14.10 ^** 19.23±18.39 ^** 20.13±17.00 ^** 34.35±21.51 ^* Yunnan Baiyao tincture 0.1ml 10 49.73±19.15 55.33±29.22 47.28±17.47 54.92±30.56 63.63±32.36 55.27±32.80 100% of the invention 0.1ml 9 29.49±17.31 35.64±21.06 38.69±29.41 48.62±41.81 46.08±37.30 41.77±37.96 50% of the invention 0.1ml 9 39.48±19.47  48.98±21.13 55.42±27.48 56.72±23.52 50.77±31.01 51.82±31.99 Invention 25% 0.1ml 8 27.07±10.73 ^* 38.91±16.28 38.10±12.09 39.05±13.84 40.95±21.49 48.56+24.39

contralateral left foot 17.37±13.75 18.89±14.49 20.65±13.73 22.75±18.43 21.65±18.04 17.15±11 91 11.87±10.94 15.85±13.74 17.82±17.16 14.38±16.73 18.50±16.97  14.57±13.61 12.37±9.95 11.28±7.10 4.17±11.30 ^* 6.60±10.85 ^* 6.42±10.03 9.20±7.72 20.16±15.01 20.78±12.44 15.56±11.01 20.45±14.97 22.06±15.02  16.09±10.57 5.35±6.28 ^* 6.80±8.32 ^* 14.74±19.99 13.04±21.00 14.24±25.93  11.81±23.89 16.15±10.86 19.46±15.02 23.65±14.95 24.36±17.16 20.47±18.12 19.48±15.28 6.96±6.57 11.47±10.86 11.83±6.22 10.73±12.36 8.82±11.74  11.67±10.16

Table 3. The present invention is to the influence of rat adjuvant arthritis systemic lesion

Group Dosage (/piece) Score Total (only) U value 0 1 2 3 4 Model comparison 1 1 0 3 3 8 Solvent 0.1ml 1 1 3 2 2 9 ＞0.05   Fusoacinol 50mg 7 1 0 0 0 8 ＜0.01   Yunnan Baiyao Tincture 0.1ml 1 3 2 2 2 10 ＞0.05   The invention is 100% 0.1ml 1 6 2 0 0 9 ＜0.05  50% of the invention 0.1ml 2 1 2 2 2 9 ＞0.05   Invention 25% 0.1ml 1 5 2 0 0 8 ＜0.05

Table 4. The present invention is on the impact of adjuvant arthritis rat body weight, immune organ and adrenal gland weight

group Dose (/kg) Number of animals (only) Body weight (X±SD, g) Organ weight index (X±SD, mg/100g) Pre-inflammatory Inflammatory 15d Inflammatory 28d Thymus spleen adrenal gland Model comparison 8 181.5±11.1 206.3±14.1 226.3±19.3  108.13±45.67 467.12±193.73 30.14±6.15 solvent 0.1ml 9 190.0±12.9 217.8±33.6 222.2±35.1 83.76±17.82 434.31±91.31 32.65±10.80 Fluocinolone Acetate 50mg 8  178.0±12.3 153.8±23.0 ^** 175.0±17.7 ^** 26.21±23.54 ^** 451.22±56.26 22.31±3.74 ^** Yunnan Baiyao Tincture 0.1ml 10  182.0±14.8 191.5±18.3 192.0±17.4 ^** 83.80±34.71 455.07±132.22 31.28±8.11 100% of the invention 0.1ml 9  192.0±24.3 207.2±17.9 204.4±41.1 94.72±43.55 420.64±71.13 32.24±11.07 50% of the invention 0.1ml 9  183.5±20.7 208.9±16.2 215.0±18.0 83.14±20.60 430.13±131.04  28.50±5.66 25% of the invention 0.1ml 8  191.5±10.3 203.1±19.4 205.5±22.1 91.05±31.30 490.69±274.19 30.44±6.94

Compared with the control group: *P<0.05, **P<0.01

2. Effect on egg white paw swelling in rats

Take 60 rats weighing 180-235 g, half male and half male, and group them according to Table 5, with 10 rats in each group. Animals in each group were smeared once according to the dose below the right hind ankle joint, and 30 minutes later, subcutaneously injected 0.1 ml of 10% fresh egg white saline solution into the foot of the medicated foot, and smeared the medicine again at the same time. Measure the foot volume before inflammation and 0.5h, 1h, 2h, 3h, 4h and 5h after inflammation. Due to the loss of medicine on the sole of the foot during the measurement, the medicine should be applied again after each measurement. The swelling rate was calculated as the change rate of the inflamed hind paw volume per mouse. The results are shown in Table 5.

Table 5. The present invention is to the impact of rat egg white paw swelling

group Dosage (ml/piece) Number of animals (only) Basal foot volume (X±SD, ml)  Swelling rate after inflammation (X±SD) 0.5h 1h 2h 3h 4h Model comparison 0.1 10 1.33±0.18 0.46±0.12 0.58±0.19 0.46±0.15 0.37±0.14 0.27±0.11 solvent 0.1 10 1.38±0.25 0.44±0.12 0.51±0.18 0.41±0.16 0.35±0.18 0.24±0.13 Yunnan Baiyao tincture 0.1 10 1.25±0.22 0.37±0.14 0.45±0.12 0.31±0.08 ^* 0.24±0.11 ^* 0.15±0.10 ^* 100% of the invention 0.1 10 1.26±0.23 0.31±0.13 ^* 0.40±0.19 ^* 0.29±0.20 ^* 0.18±0.13 ^** 0.13±0.11 ^** 50% of the invention 0.1 10 1.25±0.17 0.36±0.19 0.39±0.15 ^* 0.37±0.13 0.25±0.10 ^* 0.16±0.07 ^* Invention 25% 0.1 10 1.29±0.19 0.45±0.28 0.45±0.31 0.35±0.20 0.23±0.13 ^* 0.15±0.13 ^*

Compared with the control group: *P<0.05, **P<0.01

The experimental results show that both the three dosage groups of the present invention and the Yunnan Baiyao Tincture group can significantly inhibit the paw swelling of rats caused by egg white, and the dose-effect relationship among the groups is not obvious.

3. Effect of p-xylene on mouse auricle swelling

Take 60 mice of 21-24 g, half male and half male, and group them according to Table 6, with 10 mice in each group. Apply 0.05 ml of xylene evenly to both sides of the right ear of each mouse, and the left ear is not applied as a control. Animals in each group were smeared once 30 minutes and 1 hour after inflammation. The animal was sacrificed 1 hour after the last administration, and the same area of both ears was cut off with a puncher with a diameter of 9 mm, weighed with an electronic analytical balance, and the swelling degree was taken as the difference between the weights of the two ears. The results are shown in Table 6.

Table 6. The present invention is to the influence of xylene-induced mouse auricle swelling

Group Dosage (ml/piece) Number of animals (only)   Auricle swelling (X±SD, mg) Inhibition rate(%)

Normal saline 0.05 10 15.0±3.1 Solvent 0.05 10 13.4±3.4 10.67   Yunnan Baiyao Tincture 0.05 10 9.3±3.3 ^** 38.00   The invention is 100% 0.05 10 6.8±1.5 ^** 54.67  50% of the invention 0.05 10 8.3±2.4 ^** 44.67   Invention 25% 0.05 10 10.2±4.7 ^* 32.00

Compared with the control group: *P<0.05, **P<0.01

The experimental results show that both the three dosage groups of the present invention and the Yunnan Baiyao Tincture group can significantly inhibit the swelling of the mouse auricles induced by xylene, and the effects among the groups are dose-dependent.

2. Research on analgesic effect

1. Effect on writhing pain in mice induced by acetic acid

Take 60 mice weighing 18-20 g, half male and half male, and group them according to Table 7, with 10 mice in each group. The mice in each group were smeared with 0.1ml/mouse on the abdomen once every hour for three consecutive times. 30 minutes after the last drug application, each mouse was injected intraperitoneally with 0.6% glacial acetic acid 0.1ml/10g body weight, and the number of writhing reactions of each mouse within 15 minutes was observed and recorded. The results are shown in Table 7.

Table 7. Effect of the present invention on the pain-inducing effect of acetic acid in mice

Group Dosage (ml/piece) Number of animals (only) Twist times (X±SD, times) Inhibition rate(%) Normal saline 0.1 10 31.9±11.6 Solvent 0.1 10 29.0±19.2 9.09   Yunnan Baiyao Tincture 0.1 10 15.4±15.4 ^* 51.72   The invention is 100% 0.1 10 13.1±11.1 ^** 58.93  50% of the invention 0.1 10 20.8±13.5 ^* 34.80   Invention 25% 0.1 10 32.3±15.8

Compared with the control group: *P<0.05, **P<0.01

The experimental results show that both the high-dose dosage group of the present invention and the Yunnan Baiyao tincture group can significantly inhibit the writhing response of acetic acid-induced pain mice; there is no significant difference between the low-dose group and the blank control group.

2. Effect on formaldehyde-induced pain response in mice

Take 60 mice weighing 19-21 g, half male and half male, and group them according to Table 8, with 10 mice in each group. Animals in each group were smeared below the right hind ankle once a day at a dose of 0.05ml/animal, for 3 consecutive days. 30 minutes after the last drug application, inject 30ul of 0.5% formaldehyde subcutaneously on the right hind foot of the mouse according to the method in the literature, and immediately apply the drug once again, put it into a 500ml glass beaker, observe and record the licking and biting of the right mouse in the first 10 minutes. The time of the hind foot and the time of licking and biting the right hind foot or grasping the genitals in the last 20 minutes. The results are shown in Table 8.

Table 8. Effect of the present invention on formaldehyde-induced pain response in mice

Group Dosage (ml/piece) Number of animals (only) Licking and biting time in the first 10 minutes (X±SD, seconds) Licking and biting time in the last 20 minutes (X±SD, seconds) Normal saline 0.05 10 81.0±39.5  176.9±97.6 Solvent 0.05 10 76.2±35.0 206.2±110.5   Yunnan Baiyao Tincture 0.05 10 35.6±35.0 ^*  124.9±74.6   The invention is 100% 0.05 10 25.6±38.5 ^**  128.2±110.3  50% of the invention 0.05 10 48.6±36.9  128.6±67.9   Invention 25% 0.05 10 50.2±46.4  145.1±90.2

Compared with the control group: *P<0.05, **P<0.01

The experimental results show that both the Yunnan Baiyao tincture group and the high-dose group of the present invention have significant inhibitory effects on the formaldehyde-induced pain response in mice, and the middle and low-dose groups have a trend of inhibition without statistical difference.

3. Effect on experimental microcirculation disorder

Select 60 mice of 18-21 g, half male and half male, and group them according to Table 9, with 10 mice in each group. The laboratory temperature was maintained at 25±1°C. Anesthetized animals were anesthetized by intraperitoneal injection of 0.15ml/10g body weight of 10% urethane, fixed auricles, and placed under a microcirculation microscope with a magnification of 240 times. To observe the subject, first collect images before administration, and then intraperitoneally inject epinephrine hydrochloride 0.1 mg/kg to cause experimental microcirculation disturbance. Five minutes after the modeling, the animals in each group were sprayed with a dose of 0.01ml/auricle, and the images were collected 5 minutes after the modeling and 5, 10, and 15 minutes after the application, and the following four indicators were measured: ① Blood flow State (five grades for flow state: 0 for stagnation; 1 point for granular flow; 2 points for linear flow; 3 points for mitochondrial flow; 4 points for linear flow); ② Arteriolar diameter (A ₃ ); ③Verule diameter (V ₃ ); ④Capillary network count. Observe and record changes in various indicators. The results are shown in Tables 9, 10, 11 and 12.

Experimental results show that the present invention can obviously increase the arterioles, venule diameters and capillary network counts of mice with experimental microcirculation disorder caused by adrenaline.

Table 9. The present invention is on the impact of mouse auricle microcirculation fluid state (X ± SD, points)

grouping normal flow state 5 minutes after styling 5 minutes after administration 10 minutes after administration 15 minutes after administration Measurements change value Measurements change value Measurements change value Measurements change value physiology 3.40± 3.80± 0.42± 3.90± 0.50± 3.90± 0.50± 3.88± 0.38±

salt water 0.52 0.42 0.52 0.32 0.53 0.32 0.53 0.35 0.52 Solvent 3.50±0.53 3.80±0.42 0.30±0.48 3.90±0.32 0.40±0.52 4.00±0.00 0.50±0.53 4.00±0.00 0.50±0.53   Yunnan Baiyao Tincture 3.70±0.48 3.90±0.32 0.20±0.42 4.00±0.00 0.30±0.48 4.00±0.00 0.10±0.32 4.00±0.00 0.30±0.48   The invention is 100% 3.60±0.52 3.90±0.32 0.30±0.48 4.00±0.00 0.40±0.52 4.00±0.00 0.40±0.52 4.00±0.00 0.33±0.50  50% of the invention 3.60±0.52 3.70±0.48 0.10±0.32 3.80±0.42 0.20±0.42 3.90±0.32 0.30±0.48 3.90±0.32 0.30±0.48   Invention 25% 3.80±0.42 3.70±0.67 -0.10±0.32 3.90±0.32 0.20±0.42 3.90±0 32 0.20±0.42 3.88±0.35 0.13±0.35

Compared with the control group: P>0.05

Table 10. The present invention is on the impact of mouse auricle microcirculation capillary network count (X ± SD, individual)

group normal count Styling for 5 minutes 5 minutes after administration 10 minutes after administration 15 minutes after administration Measurements change value Measurements change value Measurements change value Measurements change value normal saline 5.90±3.28 3.70±2.45 -2.20±1.23 4.20±2.44 -170±3.16 5.10±4.04 -0.80±2.90 4.88±2.80 0.50±2.07 solvent 4.10±2.08 2.20±1.69 -1.90±1.85 3.90±3.07 -0.20±2.78 4.00±2.75 -0.10±2.56 4.40±2.95 0.30±2.71 Yunnan Baiyao tincture 5.00±2.94 3.30±2.95 -1.70±1.25 4.80±3.32 -0.20±2.53 5.50±3.72 0.50±2.27 5.90±3.28 0.90±2.02 100% of the invention 5.00±2.94 3.30±2.21 -1.70±1.70 5.60±2.01 0.60±*2.01 5.60±1.90 0.60±1.58 4.89±2.32 0.11±1.62 50% of the invention 3.90±1.96 1.90±1.29 -1.90±1.37 3.60±1.96 -0.20±2.10 4.20±2.44 0.40±1.58 3.80±2.30 -0.10±1.59 Invention 25% 3.70±2.21 2.20±2.44 -1.50±1.96 3.50±2.55 -0.20±1.87 4.10±2.51 -0.20±1.62 4.75±3.06 1.38±2.07

Compared with the control group: *P<0.05

Table 11. The present invention is to the influence of the diameter of mouse auricle microcirculation A ₃ (X ± SD, um)

grouping Normal A ₃ pipe diameter Styling 5 minutes 5 minutes after administration 10 minutes after administration 15 minutes after administration Measurements change value Measurements change value Measurements change value Measurements change value normal saline 5.93±0.93 4.42±1.56 -1.51±1.29 4.99±1.77 -0.94±1.34 5.72±1.05 -0.21±0.37 5.82±1.23 -0.09±0.44 solvent 6.76±1.27 4.68±1.72 -2.09±1.31 4.89±2.30 -1.88±2.42 5.35±1.57 -1.41±1.69 6.09±1.15 -0.68±1.15 Yunnan Baiyao Tincture 6.43±1.48 5.25±2.28 -1.18±1.52 6.35±2.31 -0.08±2.12 7.59±2.11 1.17±1.03 ^** 7.80±2.44 1.38±1.30

  The invention is 100% 6.19±0.97 4.68±1.89 -1.51±1.26 6.14±2.25 -0.06±1.80 7.02±1.99 0.83±1.72 7.34±2.23  1.33±2.21  50% of the invention 5.88±1.55 4.47±1.52 -1.41±1.45 5.67±1.58 -0.16±0.85 6.29±1.56 0.41±1.01 ^* 6.60±1.92 0.73±1.42   Invention 25% 6.92±1.30 5.15±1.66 -1.76±0.79 6.16±2.05 -0.68±1.70 6.50±1.89 -0.42±1.44 7.28±1.28 0.20±0.78

Compared with the control group: *P<0.05, **P<0.01

Table 12. The present invention is on the impact of the microcirculation V ₃ diameter of mouse auricle (X ± SD, um)

grouping Normal V ₃ pipe diameter Styling for 5 minutes 5 minutes after administration 10 minutes after administration 15 minutes after administration Measurements change value Measurements change value Measurements change value Measurements change value Normal saline 6.97±1.30 5.67±1.06 -1.30±0.89 5.93±1.61 -1.04±1.28 6.29±1.65 -0.68±1.13 6.05±1.76 -0.72±1.15 Solvent 7.13±1.72 6.50±1.58 -0.63±0.73 7.33±2.33 0.21±1.40 7.44±2.37 0.31±1.16 7.07±2.42 -0.05±1.19   Yunnan Baiyao Tincture 7.13±1.30 5.95±1.27 -1.18±0.88 7.44±1.49 0.31±1.43 8.01±1.65 0.88±1.16 ^* 8.37±1.46 1.25±1.43   The invention is 100% 6.77±0.84 6.35±0.94 -0.42±1.00 7.49±1.01 0.72±0.92 ^** 8.32±1.49 1.56±1.12 ^** 7.96±1.71 1.30±1.46 ^*  50% of the invention 7.18±1.68 6.34±1.68 -0.84±1.30 6.97±1.33 -0.21±0.82 7.39±1.14 0.21±1.41 7.80±1.15 0.62±1.03 ^*   Invention 25% 6.82±1.21 6.09±1.57 -0.42±1.80 7.28±1.94 0.31±1.84 7.33±1.54 0.57±1.03 7.74±1.96 0.78±1.76

Compared with the control group: *P<0.05, **P<0.01

Fourth, the role of anti-gouty arthritis

1. Effect on sodium urate-induced foot swelling in mice

In the experiment, 50 male mice were randomly divided into 5 groups, 10 in each group. Apply externally once a day for 3 consecutive days, and the positive drug is Snow Mountain Golden Arhat Pain Relief Film. Thirty minutes after the last administration, 0.05 ml of sodium urate saline suspension was subcutaneously injected into the right hind foot pad; the occurrence of gouty arthritis was induced. Before the inflammation and 1, 2, 4, and 6 hours after the inflammation, use a projector (6.5 times magnification) to measure the diameter of the 0.5 cm below the ankle joint of the inflamed limb; the difference before and after the inflammation is used as the index of gouty arthritis degree of swelling. Get the average number of each administration group and compare with the control group, carry out statistical test. The results show that the anti-inflammatory effect of the stock solution of the present invention on mouse gouty arthritis is very significant.

2. Sodium urate-induced paw swelling in rats

In the experiment, 50 male mice were randomly divided into 5 groups, 10 in each group. Apply externally once a day for 3 consecutive days, and the positive drug is Snow Mountain Golden Arhat Pain Relief Film. Thirty minutes after the last administration, 0.05 ml of sodium urate saline suspension was subcutaneously injected into the right hind foot pad; the occurrence of gouty arthritis was induced. Before the inflammation and 1, 2, 4, and 6 hours after the inflammation, use a projector (6.5 times magnification) to measure the diameter of the 0.5 cm below the ankle joint of the inflamed limb; the difference before and after the inflammation is used as the index of gouty arthritis degree of swelling. Get the average number of each administration group and compare with the control group, carry out statistical test. The results show that the anti-inflammatory effect of the stock solution of the invention on rat gouty arthritis is very significant.

5. Effect on breast hyperplasia

1. Effect on mouse mammary gland hyperplasia induced by diethylstilbestrol

Sixty female mice were randomly divided into 6 groups, 10 in each group. Except for the normal control group, mice in other groups were intraperitoneally injected with diethylstilbestrol (15 mg/kg), once a day at intervals, for 10 consecutive times. While modeling, each administration group was externally applied with different doses of the present invention; Ruzengning Capsule, normal control group and model control group, administered once a day for 20 consecutive days. One hour after the last administration, the animals were anesthetized with pentobarbital sodium, and the diameters of the anterior axillary breasts of the mice in each group were measured with a precision vernier caliper; the mammary gland tissues were taken as slices, and scored according to the criteria for judging mammary gland tissue hyperplasia and lesions. The results can be seen , each dose group of the present invention can significantly inhibit mouse mammary gland hyperplasia caused by diethylstilbestrol, and reduce the degree of pathological changes.

2. Effect on rat mammary gland hyperplasia induced by diethylstilbestrol

55 female rats were randomly divided into 6 groups with 10 rats in each group. Except for the normal control group, rats in other groups were intraperitoneally injected with diethylstilbestrol (20 mg/kg), once a day at intervals for 10 consecutive times. While modeling, each administration group was externally applied with different doses of the present invention; Ruzengning Capsule, normal control group and model control group, administered once a day for 20 consecutive days. One hour after the last administration, the animals were anesthetized with pentobarbital sodium, and the diameter of the anterior axillary breast of the rats in each group was measured with a precision vernier caliper; Each dose group of the present invention can significantly inhibit the hyperplasia of mammary glands in rats caused by diethylstilbestrol, and reduce the degree of mammary gland lesions.

Detailed ways

Example 1:

Take 60 parts of borneol, 60 parts of menthol, 0.8 parts of musk, and add an appropriate amount of ethanol to dissolve it, and the remaining 180 parts of Aesculus, 180 parts of jade grape root, 180 parts of golden leaf, 180 parts of hemp grass, 180 parts of golden iron lock, and 180 parts of Artemisia spp. 180 parts, 180 parts of Diancaowu, 180 parts of torch root, 180 parts of Erigeron breviscapus, 180 parts of Panax notoginseng, 180 parts of star anise lotus, 180 parts of chrysanthemum, 180 parts of mast, 180 parts of Baiji, 180 parts of Angelica dahurica, 60 parts of licorice were crushed into coarse powder, mixed evenly, infiltrated with a certain concentration of ethanol, percolated, collected filtrate, refrigerated and filtered, and set aside. Take the medicinal film resin and add it to the spare medicinal solution, stir evenly, swell at room temperature, heat in a water bath to dissolve, add ethanol solution such as menthol and an appropriate amount of glycerin, stir evenly, and pack separately to obtain the gel.

Example 2:

Borneol 60, menthol 60, musk 0.8 add ethanol to dissolve it, the rest of the horse chestnut 180, jade grape root 180, gold leaf 180, hemp grass 180, gold iron lock 180, snow on a stick of Artemisia 180, Diancao 180, torch flower Root 180, Erigeron 180, Panax notoginseng 180, Star anise 180, Chonglou 180, Fructus 180, Baiji 180, Angelica dahurica 180, Licorice 60, pulverize into coarse powder, mix well, infiltrate with a certain concentration of ethanol, percolate, Collect the filtrate, add the above-mentioned borneol and other solutions, refrigerate, filter, and pack separately to obtain the liniment.

Example 3:

Aescin 180, jade grape root 180, gold leaf 180, hemp grass 180, golden iron lock 180, a branch of Artemisia spp. Lou 180, Zhizi 180, Baiji 180, Angelica dahurica 180, Licorice 60 are crushed into coarse powder, mixed evenly, infiltrated with a certain concentration of ethanol, percolated, collected filtrate, filtered, take borneol 60, menthol 60, musk 0.8 to dissolve In the filtrate, refrigerate and filter, add polysorbate-80, propylene glycol and the liquid, mix well, and let stand. Pour the liquid medicine into a clean container, and press in propane butane gas with a press machine to obtain an aerosol.

Claims (2)

1. An external pharmaceutical composition for treating swelling and pain, characterized in that it is an external dosage form made of the following raw materials by weight: Aescin 160-200, Panax notoginseng 160-200, Artemisia spp. 160-200, Jade grape root 160-200, gold leaf 160-200, hemp grass 160-200, gold iron lock 160-200, Dian grass root 160-200, torch flower root 160-200, erigantula 160-200, star anise lotus 160-200 , Chonglou 160-200, Mastia 160-200, Baiji 160-200, Angelica dahurica 160-200, Licorice 50-70, Borneol 50-70, Menthol 50-70, Musk 0.4-1. 2. The external pharmaceutical composition for treating swelling and pain according to claim 1, which is characterized in that it is an external dosage form made of the following raw materials by weight: Aescin 180, Panax notoginseng 180, Artemisia spp. Grape Root 180, Golden Leaf 180, Hemp Grass 180, Jin Tiesuo 180, Diancaowu 180, Torch Flower Root 180, Erigeron 180, Star Anise 180, Chonglou 180, Mastiff 180, Baiji 180, Angelica dahurica 180, Licorice 60, borneol 60, menthol 60, musk 0.8.